The Minnesota State Senate has introduced a resolution designating May 4 to 10, 2025, as Tardive Dyskinesia Awareness Week. This initiative aims to raise awareness about tardive dyskinesia (TD), a movement disorder that can occur in individuals treated with dopamine receptor blocking agents (DRBAs), such as antipsychotic medications, for serious mental health and gastrointestinal conditions. It is estimated that around 800,000 people in the U.S. are affected by TD, with a significant portion remaining undiagnosed. The resolution emphasizes the importance of recognizing the symptoms and impacts of TD, as even mild cases can lead to various physical, social, and emotional challenges.

The resolution also highlights the necessity for regular monitoring and screening for TD among patients using DRBAs, as recommended by the American Psychiatric Association. Furthermore, it notes that clinical research has resulted in FDA-approved treatments for adults with TD. By designating this week, the Minnesota State Senate aims to encourage the public and medical community to become more informed about tardive dyskinesia, ultimately fostering better understanding and support for those affected by the disorder.